Back to discover
Disease
Childhood onset asthma
Late-stage therapeutic development
Also known as asthma of childhood, childhood asthma, paediatric asthma, pediatric asthma.
24
Clinical trials
12
Associated genes
12
Related proteins
Current focus
Chitinase-3-like 1 biologyTherapeutic developmentToll-like 1 biologyInflammation & immunity
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
Executive briefingUpdating summary…Momentum: Moderate
Key developments
- 6 clinical trials expected to report results, the earliest in Q3 2027.
Upcoming Milestones
- Q3 2027TAPER: A Prospective, Interventional, Multicentre, Single-Arm, Phase 3b Study to Evaluate the Step-Down of Maintenance Therapy in Patients With Severe Asthma Treated With Tezepelumab
- Q4 2028A Randomized, Double-Blind, Placebo-Controlled Phase Ⅲ Clinical Study of Evaluating the Efficacy and Safety of CM326 in Subjects With Moderate to Severe Asthma
- Q1 2029A Multinational, Investigator-initiated, Parallel Group, Randomised, Double-blind, Placebo-controlled Phase 3b Superiority Trial Assessing the Effect of Dupilumab on Inducing Clinical Remission Outcomes in At-risk Type-2 Inflammatory Asthma (HOTHOT)
- Q1 2029A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of GB-0895 Adjunctive Therapy in Adults and Adolescents With Severe Uncontrolled Asthma
- Q4 2029Individualizing Treatment for Asthma in Primary Care (Full Study)
Major developments
Upcoming trial readoutHigh impact
Results expected Q1 20292026-08-07
Upcoming trial readoutHigh impact
Results expected Q3 20272026-06-25
Clinical MilestonesView all 15Hide
Results expected
- 2026-08-07A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of GB-0895 Adjunctive Therapy in Adults and Adolescents With Severe Uncontrolled AsthmaResults expected Q1 2029
- 2026-06-25TAPER: A Prospective, Interventional, Multicentre, Single-Arm, Phase 3b Study to Evaluate the Step-Down of Maintenance Therapy in Patients With Severe Asthma Treated With TezepelumabResults expected Q3 2027
- 2026-06-25The MODIFY Study: A Phase 3b/4 Randomized, Double-blind, Placebo-controlled, Multi-centre Study Evaluating the Impact of Early Intervention With Depemokimab on Exacerbation Rate, Clinical Remission, Lung Function Decline, and Safety in Adults and Adolescents With at Risk Type 2 Asthma, Conducted up to 156 WeeksResults expected Q3 2030
- 2026-04-28A Randomized, Double-Blind, Placebo-Controlled Phase Ⅲ Clinical Study of Evaluating the Efficacy and Safety of CM326 in Subjects With Moderate to Severe AsthmaResults expected Q4 2028
- 2026-03-04A Multinational, Investigator-initiated, Parallel Group, Randomised, Double-blind, Placebo-controlled Phase 3b Superiority Trial Assessing the Effect of Dupilumab on Inducing Clinical Remission Outcomes in At-risk Type-2 Inflammatory Asthma (HOTHOT)Results expected Q1 2029
Recently completed
- 2026-06-24The ALOHA Trial: Addressing Quality of Life, Clinical Outcomes, and Mechanisms in Uncontrolled Asthma Following the DASH Dietary PatternCompleted
- 2026-06-23REVErsing Airway Remodelling With Tezepelumab : a Protocol for a Double-blind Randomized Controlled Trial for Patients With AsthmaCompleted
- 2026-04-26A Histamine Pharmacodynamic Biomarker to Guide Treatment in Pediatric AsthmaCompleted
- 2026-01-31The Efficacy and Mechanisms of Action of n-3 Poly-unsaturated Fatty Acid Supplementation in People With Non-steroidal Exacerbated Airways Disease and Uncontrolled AsthmaCompleted
- 2025-10-01A Pilot Interventional Study to Evaluate the Safety and Tolerability of Mirabegron and Montelukast in Patients With Liver CirrhosisCompleted
Other updates
- 2027-11-01Phase 3, Multicenter, Randomized, Parallel-Group, Open-Label, Comparative Non-Inferiority Fixed-Dose Combination Formoterol 6 mcg/Fluticasone 125 mcg Versus Alenia® (Formoterol 6 mcg/Budesonide 200 mcg) in the Treatment of Moderate AsthmaWithdrawn
- 2026-12-01A Prospective, Blinded, Cross-Over Trial of the Exposure-Response Relationship of Terbutaline Sulfate in Adults With AsthmaWithdrawn
- 2025-12-08A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Efficacy, Safety, and Tolerability of Dexpramipexole Administered Orally for 52 Weeks in Participants With Severe Eosinophilic AsthmaTerminated
+7 more in the activity timeline below
Activity timeline15
- 2027-11-01ClinicalPhase 3, Multicenter, Randomized, Parallel-Group, Open-Label, Comparative Non-Inferiority Fixed-Dose Combination Formoterol 6 mcg/Fluticasone 125 mcg Versus Alenia® (Formoterol 6 mcg/Budesonide 200 mcg) in the Treatment of Moderate AsthmaWithdrawn
- 2026-12-01ClinicalA Prospective, Blinded, Cross-Over Trial of the Exposure-Response Relationship of Terbutaline Sulfate in Adults With AsthmaWithdrawn
- 2026-08-07ClinicalA Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of GB-0895 Adjunctive Therapy in Adults and Adolescents With Severe Uncontrolled AsthmaResults expected Q1 2029
- 2026-06-25ClinicalTAPER: A Prospective, Interventional, Multicentre, Single-Arm, Phase 3b Study to Evaluate the Step-Down of Maintenance Therapy in Patients With Severe Asthma Treated With TezepelumabResults expected Q3 2027
- 2026-06-25ClinicalThe MODIFY Study: A Phase 3b/4 Randomized, Double-blind, Placebo-controlled, Multi-centre Study Evaluating the Impact of Early Intervention With Depemokimab on Exacerbation Rate, Clinical Remission, Lung Function Decline, and Safety in Adults and Adolescents With at Risk Type 2 Asthma, Conducted up to 156 WeeksResults expected Q3 2030
- 2026-06-24ClinicalThe ALOHA Trial: Addressing Quality of Life, Clinical Outcomes, and Mechanisms in Uncontrolled Asthma Following the DASH Dietary PatternCompleted
- 2026-06-23ClinicalREVErsing Airway Remodelling With Tezepelumab : a Protocol for a Double-blind Randomized Controlled Trial for Patients With AsthmaCompleted
- 2026-04-28ClinicalA Randomized, Double-Blind, Placebo-Controlled Phase Ⅲ Clinical Study of Evaluating the Efficacy and Safety of CM326 in Subjects With Moderate to Severe AsthmaResults expected Q4 2028
- 2026-04-26ClinicalA Histamine Pharmacodynamic Biomarker to Guide Treatment in Pediatric AsthmaCompleted
- 2026-03-04ClinicalA Multinational, Investigator-initiated, Parallel Group, Randomised, Double-blind, Placebo-controlled Phase 3b Superiority Trial Assessing the Effect of Dupilumab on Inducing Clinical Remission Outcomes in At-risk Type-2 Inflammatory Asthma (HOTHOT)Results expected Q1 2029
Clinical trials
The current development programme across all trial phases.
Clinical programme
24
6
18
6
Late-stage studies
Recruiting
Recently completed
Associated genes
Genes associated with this disease in the canonical knowledge graph (Open Targets evidence). Number shows the association score.
Disease biology
Proteins whose encoding gene is associated with this disease, reached through the canonical gene→disease graph. Number shows the gene's association score.
Interleukin-4 receptor subunit alphavia IL4R0.51Interleukin-1 receptor-like 1via IL1RL10.50Interleukin-33via IL330.50Toll-like receptor 1via TLR10.50Interleukin-13via IL130.49Nucleotide-binding oligomerization domain-containing protein 2via NOD20.46Protein kinase C theta typevia PRKCQ0.45Tumor necrosis factor ligand superfamily member 4via TNFSF40.43C-C motif chemokine 20via CCL200.40T-box transcription factor TBX21via TBX210.38Interleukin-4via IL40.18Chitinase-3-like protein 1via CHI3L10.17
Reference
Authoritative identity, definition & identifiers.
Synonyms
asthma of childhood, childhood asthma, paediatric asthma, pediatric asthma
References & data sources
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Related entities are derived from literature co-mention (studied together) — associative, not causal.